title: [Dynamics of humoral antiendotoxin immunity in patients with unhospital pneumonia during therapy Bifi-form Kids].
abstract: The aim of the work was to study the total level of antiendotoxin antibodies in blood serum of children of early age with community-Acquired pneumonia (CAP), with intestines dysbacteriosis in dynamics of the disease, and correction of intestine dysbiotic changes using modified regimen of a probiotic Bifi-form Kids drug administration. In the course of the study we found that acute period of CAP had considerable changes of antiendotoxin immunity which declared clear increase in the level of anti-et-antibodies in blood and concentration of the last ones directly depended on severity of the disease. After probiotic Bifi-form Kids had been prescribed in a complex treatment of children with CAP, the level of anti-et-antibodies considerably decreased in comparison with children who did not take this probiotic. After treatment with high dosages of the probiotic of children with severe CAP, the indicator of total anti-et-antibodies considerably decreased in comparison with the children who received Bifi-form Kids probiotic in a standard dosage. The obtained data testifies on necessity of inclusion in a complex treatment of probiotica in higher doses during severe course of the disease.
authors.forename: O I
authors.initials: OI
authors.lastname: Smiian
authors.forename: O G
authors.initials: OG
authors.lastname: Vasyl'eva
mesh_terms: D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000907:Antibodies, Bacterial / Q000032:analysis* / Q000276:immunology; D001644:Bifidobacterium / Q000502:physiology; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D004731:Endotoxins / Q000276:immunology; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D056724:Immunity, Humoral / Q000187:drug effects*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010045:Outpatients; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014455:Ukraine
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D004731:Endotoxins